Our
Pipeline
We bring more than 35 years of innovation to the ADC field. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines.
Clinical Pipeline
Compound
Preclinical
Phase 1
Phase 2
Phase 3
Mirvetuximab Soravtansine
TARGET: Folate receptor alpha (FRa)
Ovarian monotherapy
Ovarian with bevacizumab
Ovarian with carboplatin and bevacizumab
IMGN779
TARGET: CD33
Acute myeloid leukemia
IMGN632
TARGET: CD123
Acute Myeloid Lukemia and Blastic Plasmactoid Dentric Cell Neoplasm
IMGC936
TARGET: ADAM9
MacroGenics
Co-Development
Early Stage Pipeline
Program
Discovery
Preclinical Research
Preclinical Development
Exploratory
Exploratory
Ovarian Next Generation
Ovarian Next Generation
Hematologic Malignancies
Hematologic Malignancies
cMet
cMet
partnerships
In addition to our own, proprietary pipeline of ADC candidates, we have a number of partnerships and collaborations in place that leverage our technology – and those of our collaborators – to address unmet medical needs. We are constantly seeking out innovative partnerships with the goal of advancing science, gaining access to complimentary capabilities, strengthening our financial position, and creating more value for ImmunoGen.
Examples of our partnerships include a strategic collaboration with CytomX Therapeutics to develop probody drug conjugate (PDC) therapies, and a strategic collaboration and option agreement with Jazz Pharmaceuticals to develop and commercialize hematology-related ADCs.
legacy platform deals
Our technology platform has been the basis for a number of high-value partnerships for the company, including the first-ever ADC approved as a treatment option for HER2-positive breast cancer, which is marketed by Roche, called Kadcyla®.
In addition to Roche, we have ADC technology deals in place with Amgen, Bayer, Biotest, Sanofi, and Takeda.
